Pharma & Healthcare
Global Gastrointestinal Stromal Tumor Drug Market Research Report 2026
- Mar 17, 26
- ID: 736837
- Pages: 143
- Figures: 139
- Views: 7
This report delivers a comprehensive overview of the global Gastrointestinal Stromal Tumor Drug market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Gastrointestinal Stromal Tumor Drug. The Gastrointestinal Stromal Tumor Drug market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Gastrointestinal Stromal Tumor Drug market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Gastrointestinal Stromal Tumor Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Novartis
Bayer Pharmaceuticals
Glenmark Pharmaceuticals Ltd.
Sun Pharmaceuticals
Actavis Generics
Dr. Reddy's Laboratories
Teva Pharmaceutical Industries Ltd.
Apotex Inc.
Mylan Pharms Inc.
Bulat Pharmaceutical
MSN Laboratories
Vannsh Life Sciences
Beacon Pharmaceuticals
Drug International
Deciphera Pharmaceuticals
CSPC Pharmaceuticals
Hansoh Pharmaceuticals
Kelun Pharmaceuticals
Zai Lab
CStone Pharmaceuticals
China Biopharmaceuticals
Segment by Type
Imatinib
Sunitinib
Regorafenib
Ripretinib
Others
by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Gastrointestinal Stromal Tumor Drug manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Gastrointestinal Stromal Tumor Drug sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Gastrointestinal Stromal Tumor Drug market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Gastrointestinal Stromal Tumor Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Novartis
Bayer Pharmaceuticals
Glenmark Pharmaceuticals Ltd.
Sun Pharmaceuticals
Actavis Generics
Dr. Reddy's Laboratories
Teva Pharmaceutical Industries Ltd.
Apotex Inc.
Mylan Pharms Inc.
Bulat Pharmaceutical
MSN Laboratories
Vannsh Life Sciences
Beacon Pharmaceuticals
Drug International
Deciphera Pharmaceuticals
CSPC Pharmaceuticals
Hansoh Pharmaceuticals
Kelun Pharmaceuticals
Zai Lab
CStone Pharmaceuticals
China Biopharmaceuticals
Segment by Type
Imatinib
Sunitinib
Regorafenib
Ripretinib
Others
by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Gastrointestinal Stromal Tumor Drug manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Gastrointestinal Stromal Tumor Drug sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Gastrointestinal Stromal Tumor Drug Market Overview
1.1 Product Definition
1.2 Gastrointestinal Stromal Tumor Drug by Type
1.2.1 Global Gastrointestinal Stromal Tumor Drug Market Value by Type: 2025 vs 2032
1.2.2 Imatinib
1.2.3 Sunitinib
1.2.4 Regorafenib
1.2.5 Ripretinib
1.2.6 Others
1.3 Gastrointestinal Stromal Tumor Drug by Application
1.3.1 Global Gastrointestinal Stromal Tumor Drug Market Value by Application: 2025 vs 2032
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Gastrointestinal Stromal Tumor Drug Market Size Estimates and Forecasts
1.4.1 Global Gastrointestinal Stromal Tumor Drug Revenue 2021–2032
1.4.2 Global Gastrointestinal Stromal Tumor Drug Sales 2021–2032
1.4.3 Global Gastrointestinal Stromal Tumor Drug Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Gastrointestinal Stromal Tumor Drug Market Competition by Manufacturers
2.1 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Manufacturers (2021–2026)
2.2 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Gastrointestinal Stromal Tumor Drug Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Gastrointestinal Stromal Tumor Drug, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Gastrointestinal Stromal Tumor Drug, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Gastrointestinal Stromal Tumor Drug, Product Types and Applications
2.7 Global Key Manufacturers of Gastrointestinal Stromal Tumor Drug, Date of Entry into the Industry
2.8 Global Gastrointestinal Stromal Tumor Drug Market Competitive Situation and Trends
2.8.1 Global Gastrointestinal Stromal Tumor Drug Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Gastrointestinal Stromal Tumor Drug Players Market Share by Revenue
2.8.3 Global Gastrointestinal Stromal Tumor Drug Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Gastrointestinal Stromal Tumor Drug Market Scenario by Region
3.1 Global Gastrointestinal Stromal Tumor Drug Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2021–2032
3.2.1 Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2021–2026
3.2.2 Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2027–2032
3.3 Global Gastrointestinal Stromal Tumor Drug Revenue by Region: 2021–2032
3.3.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Region: 2021–2026
3.3.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Region: 2027–2032
3.4 North America Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Country
3.4.1 North America Gastrointestinal Stromal Tumor Drug Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Gastrointestinal Stromal Tumor Drug Sales by Country (2021–2032)
3.4.3 North America Gastrointestinal Stromal Tumor Drug Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Country
3.5.1 Europe Gastrointestinal Stromal Tumor Drug Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Gastrointestinal Stromal Tumor Drug Sales by Country (2021–2032)
3.5.3 Europe Gastrointestinal Stromal Tumor Drug Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Gastrointestinal Stromal Tumor Drug Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Gastrointestinal Stromal Tumor Drug Sales by Region (2021–2032)
3.6.3 Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Country
3.7.1 Latin America Gastrointestinal Stromal Tumor Drug Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Gastrointestinal Stromal Tumor Drug Sales by Country (2021–2032)
3.7.3 Latin America Gastrointestinal Stromal Tumor Drug Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (2021–2032)
3.8.3 Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Gastrointestinal Stromal Tumor Drug Sales by Type (2021–2032)
4.1.1 Global Gastrointestinal Stromal Tumor Drug Sales by Type (2021–2026)
4.1.2 Global Gastrointestinal Stromal Tumor Drug Sales by Type (2027–2032)
4.1.3 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2021–2032)
4.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2021–2032)
4.2.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2021–2026)
4.2.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2027–2032)
4.2.3 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2021–2032)
4.3 Global Gastrointestinal Stromal Tumor Drug Price by Type (2021–2032)
5 Segment by Application
5.1 Global Gastrointestinal Stromal Tumor Drug Sales by Application (2021–2032)
5.1.1 Global Gastrointestinal Stromal Tumor Drug Sales by Application (2021–2026)
5.1.2 Global Gastrointestinal Stromal Tumor Drug Sales by Application (2027–2032)
5.1.3 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2021–2032)
5.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2021–2032)
5.2.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2021–2026)
5.2.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2027–2032)
5.2.3 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2021–2032)
5.3 Global Gastrointestinal Stromal Tumor Drug Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Novartis Gastrointestinal Stromal Tumor Drug Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Bayer Pharmaceuticals
6.2.1 Bayer Pharmaceuticals Company Information
6.2.2 Bayer Pharmaceuticals Description and Business Overview
6.2.3 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.2.5 Bayer Pharmaceuticals Recent Developments/Updates
6.3 Glenmark Pharmaceuticals Ltd.
6.3.1 Glenmark Pharmaceuticals Ltd. Company Information
6.3.2 Glenmark Pharmaceuticals Ltd. Description and Business Overview
6.3.3 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
6.3.5 Glenmark Pharmaceuticals Ltd. Recent Developments/Updates
6.4 Sun Pharmaceuticals
6.4.1 Sun Pharmaceuticals Company Information
6.4.2 Sun Pharmaceuticals Description and Business Overview
6.4.3 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.4.5 Sun Pharmaceuticals Recent Developments/Updates
6.5 Actavis Generics
6.5.1 Actavis Generics Company Information
6.5.2 Actavis Generics Description and Business Overview
6.5.3 Actavis Generics Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Actavis Generics Gastrointestinal Stromal Tumor Drug Product Portfolio
6.5.5 Actavis Generics Recent Developments/Updates
6.6 Dr. Reddy's Laboratories
6.6.1 Dr. Reddy's Laboratories Company Information
6.6.2 Dr. Reddy's Laboratories Description and Business Overview
6.6.3 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
6.6.5 Dr. Reddy's Laboratories Recent Developments/Updates
6.7 Teva Pharmaceutical Industries Ltd.
6.7.1 Teva Pharmaceutical Industries Ltd. Company Information
6.7.2 Teva Pharmaceutical Industries Ltd. Description and Business Overview
6.7.3 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
6.7.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
6.8 Apotex Inc.
6.8.1 Apotex Inc. Company Information
6.8.2 Apotex Inc. Description and Business Overview
6.8.3 Apotex Inc. Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Apotex Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
6.8.5 Apotex Inc. Recent Developments/Updates
6.9 Mylan Pharms Inc.
6.9.1 Mylan Pharms Inc. Company Information
6.9.2 Mylan Pharms Inc. Description and Business Overview
6.9.3 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
6.9.5 Mylan Pharms Inc. Recent Developments/Updates
6.10 Bulat Pharmaceutical
6.10.1 Bulat Pharmaceutical Company Information
6.10.2 Bulat Pharmaceutical Description and Business Overview
6.10.3 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Product Portfolio
6.10.5 Bulat Pharmaceutical Recent Developments/Updates
6.11 MSN Laboratories
6.11.1 MSN Laboratories Company Information
6.11.2 MSN Laboratories Description and Business Overview
6.11.3 MSN Laboratories Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 MSN Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
6.11.5 MSN Laboratories Recent Developments/Updates
6.12 Vannsh Life Sciences
6.12.1 Vannsh Life Sciences Company Information
6.12.2 Vannsh Life Sciences Description and Business Overview
6.12.3 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Product Portfolio
6.12.5 Vannsh Life Sciences Recent Developments/Updates
6.13 Beacon Pharmaceuticals
6.13.1 Beacon Pharmaceuticals Company Information
6.13.2 Beacon Pharmaceuticals Description and Business Overview
6.13.3 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.13.5 Beacon Pharmaceuticals Recent Developments/Updates
6.14 Drug International
6.14.1 Drug International Company Information
6.14.2 Drug International Description and Business Overview
6.14.3 Drug International Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Drug International Gastrointestinal Stromal Tumor Drug Product Portfolio
6.14.5 Drug International Recent Developments/Updates
6.15 Deciphera Pharmaceuticals
6.15.1 Deciphera Pharmaceuticals Company Information
6.15.2 Deciphera Pharmaceuticals Description and Business Overview
6.15.3 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.15.5 Deciphera Pharmaceuticals Recent Developments/Updates
6.16 CSPC Pharmaceuticals
6.16.1 CSPC Pharmaceuticals Company Information
6.16.2 CSPC Pharmaceuticals Description and Business Overview
6.16.3 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.16.5 CSPC Pharmaceuticals Recent Developments/Updates
6.17 Hansoh Pharmaceuticals
6.17.1 Hansoh Pharmaceuticals Company Information
6.17.2 Hansoh Pharmaceuticals Description and Business Overview
6.17.3 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.17.5 Hansoh Pharmaceuticals Recent Developments/Updates
6.18 Kelun Pharmaceuticals
6.18.1 Kelun Pharmaceuticals Company Information
6.18.2 Kelun Pharmaceuticals Description and Business Overview
6.18.3 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.18.5 Kelun Pharmaceuticals Recent Developments/Updates
6.19 Zai Lab
6.19.1 Zai Lab Company Information
6.19.2 Zai Lab Description and Business Overview
6.19.3 Zai Lab Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.19.4 Zai Lab Gastrointestinal Stromal Tumor Drug Product Portfolio
6.19.5 Zai Lab Recent Developments/Updates
6.20 CStone Pharmaceuticals
6.20.1 CStone Pharmaceuticals Company Information
6.20.2 CStone Pharmaceuticals Description and Business Overview
6.20.3 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.20.4 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.20.5 CStone Pharmaceuticals Recent Developments/Updates
6.21 China Biopharmaceuticals
6.21.1 China Biopharmaceuticals Company Information
6.21.2 China Biopharmaceuticals Description and Business Overview
6.21.3 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.21.4 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.21.5 China Biopharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Gastrointestinal Stromal Tumor Drug Industry Chain Analysis
7.2 Gastrointestinal Stromal Tumor Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Gastrointestinal Stromal Tumor Drug Production Mode & Process Analysis
7.4 Gastrointestinal Stromal Tumor Drug Sales and Marketing
7.4.1 Gastrointestinal Stromal Tumor Drug Sales Channels
7.4.2 Gastrointestinal Stromal Tumor Drug Distributors
7.5 Gastrointestinal Stromal Tumor Drug Customer Analysis
8 Gastrointestinal Stromal Tumor Drug Market Dynamics
8.1 Gastrointestinal Stromal Tumor Drug Industry Trends
8.2 Gastrointestinal Stromal Tumor Drug Market Drivers
8.3 Gastrointestinal Stromal Tumor Drug Market Challenges
8.4 Gastrointestinal Stromal Tumor Drug Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Gastrointestinal Stromal Tumor Drug by Type
1.2.1 Global Gastrointestinal Stromal Tumor Drug Market Value by Type: 2025 vs 2032
1.2.2 Imatinib
1.2.3 Sunitinib
1.2.4 Regorafenib
1.2.5 Ripretinib
1.2.6 Others
1.3 Gastrointestinal Stromal Tumor Drug by Application
1.3.1 Global Gastrointestinal Stromal Tumor Drug Market Value by Application: 2025 vs 2032
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Gastrointestinal Stromal Tumor Drug Market Size Estimates and Forecasts
1.4.1 Global Gastrointestinal Stromal Tumor Drug Revenue 2021–2032
1.4.2 Global Gastrointestinal Stromal Tumor Drug Sales 2021–2032
1.4.3 Global Gastrointestinal Stromal Tumor Drug Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Gastrointestinal Stromal Tumor Drug Market Competition by Manufacturers
2.1 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Manufacturers (2021–2026)
2.2 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Gastrointestinal Stromal Tumor Drug Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Gastrointestinal Stromal Tumor Drug, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Gastrointestinal Stromal Tumor Drug, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Gastrointestinal Stromal Tumor Drug, Product Types and Applications
2.7 Global Key Manufacturers of Gastrointestinal Stromal Tumor Drug, Date of Entry into the Industry
2.8 Global Gastrointestinal Stromal Tumor Drug Market Competitive Situation and Trends
2.8.1 Global Gastrointestinal Stromal Tumor Drug Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Gastrointestinal Stromal Tumor Drug Players Market Share by Revenue
2.8.3 Global Gastrointestinal Stromal Tumor Drug Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Gastrointestinal Stromal Tumor Drug Market Scenario by Region
3.1 Global Gastrointestinal Stromal Tumor Drug Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2021–2032
3.2.1 Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2021–2026
3.2.2 Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2027–2032
3.3 Global Gastrointestinal Stromal Tumor Drug Revenue by Region: 2021–2032
3.3.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Region: 2021–2026
3.3.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Region: 2027–2032
3.4 North America Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Country
3.4.1 North America Gastrointestinal Stromal Tumor Drug Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Gastrointestinal Stromal Tumor Drug Sales by Country (2021–2032)
3.4.3 North America Gastrointestinal Stromal Tumor Drug Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Country
3.5.1 Europe Gastrointestinal Stromal Tumor Drug Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Gastrointestinal Stromal Tumor Drug Sales by Country (2021–2032)
3.5.3 Europe Gastrointestinal Stromal Tumor Drug Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Gastrointestinal Stromal Tumor Drug Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Gastrointestinal Stromal Tumor Drug Sales by Region (2021–2032)
3.6.3 Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Country
3.7.1 Latin America Gastrointestinal Stromal Tumor Drug Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Gastrointestinal Stromal Tumor Drug Sales by Country (2021–2032)
3.7.3 Latin America Gastrointestinal Stromal Tumor Drug Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (2021–2032)
3.8.3 Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Gastrointestinal Stromal Tumor Drug Sales by Type (2021–2032)
4.1.1 Global Gastrointestinal Stromal Tumor Drug Sales by Type (2021–2026)
4.1.2 Global Gastrointestinal Stromal Tumor Drug Sales by Type (2027–2032)
4.1.3 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2021–2032)
4.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2021–2032)
4.2.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2021–2026)
4.2.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2027–2032)
4.2.3 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2021–2032)
4.3 Global Gastrointestinal Stromal Tumor Drug Price by Type (2021–2032)
5 Segment by Application
5.1 Global Gastrointestinal Stromal Tumor Drug Sales by Application (2021–2032)
5.1.1 Global Gastrointestinal Stromal Tumor Drug Sales by Application (2021–2026)
5.1.2 Global Gastrointestinal Stromal Tumor Drug Sales by Application (2027–2032)
5.1.3 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2021–2032)
5.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2021–2032)
5.2.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2021–2026)
5.2.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2027–2032)
5.2.3 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2021–2032)
5.3 Global Gastrointestinal Stromal Tumor Drug Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Novartis Gastrointestinal Stromal Tumor Drug Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Bayer Pharmaceuticals
6.2.1 Bayer Pharmaceuticals Company Information
6.2.2 Bayer Pharmaceuticals Description and Business Overview
6.2.3 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.2.5 Bayer Pharmaceuticals Recent Developments/Updates
6.3 Glenmark Pharmaceuticals Ltd.
6.3.1 Glenmark Pharmaceuticals Ltd. Company Information
6.3.2 Glenmark Pharmaceuticals Ltd. Description and Business Overview
6.3.3 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
6.3.5 Glenmark Pharmaceuticals Ltd. Recent Developments/Updates
6.4 Sun Pharmaceuticals
6.4.1 Sun Pharmaceuticals Company Information
6.4.2 Sun Pharmaceuticals Description and Business Overview
6.4.3 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.4.5 Sun Pharmaceuticals Recent Developments/Updates
6.5 Actavis Generics
6.5.1 Actavis Generics Company Information
6.5.2 Actavis Generics Description and Business Overview
6.5.3 Actavis Generics Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Actavis Generics Gastrointestinal Stromal Tumor Drug Product Portfolio
6.5.5 Actavis Generics Recent Developments/Updates
6.6 Dr. Reddy's Laboratories
6.6.1 Dr. Reddy's Laboratories Company Information
6.6.2 Dr. Reddy's Laboratories Description and Business Overview
6.6.3 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
6.6.5 Dr. Reddy's Laboratories Recent Developments/Updates
6.7 Teva Pharmaceutical Industries Ltd.
6.7.1 Teva Pharmaceutical Industries Ltd. Company Information
6.7.2 Teva Pharmaceutical Industries Ltd. Description and Business Overview
6.7.3 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
6.7.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
6.8 Apotex Inc.
6.8.1 Apotex Inc. Company Information
6.8.2 Apotex Inc. Description and Business Overview
6.8.3 Apotex Inc. Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Apotex Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
6.8.5 Apotex Inc. Recent Developments/Updates
6.9 Mylan Pharms Inc.
6.9.1 Mylan Pharms Inc. Company Information
6.9.2 Mylan Pharms Inc. Description and Business Overview
6.9.3 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
6.9.5 Mylan Pharms Inc. Recent Developments/Updates
6.10 Bulat Pharmaceutical
6.10.1 Bulat Pharmaceutical Company Information
6.10.2 Bulat Pharmaceutical Description and Business Overview
6.10.3 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Product Portfolio
6.10.5 Bulat Pharmaceutical Recent Developments/Updates
6.11 MSN Laboratories
6.11.1 MSN Laboratories Company Information
6.11.2 MSN Laboratories Description and Business Overview
6.11.3 MSN Laboratories Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 MSN Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
6.11.5 MSN Laboratories Recent Developments/Updates
6.12 Vannsh Life Sciences
6.12.1 Vannsh Life Sciences Company Information
6.12.2 Vannsh Life Sciences Description and Business Overview
6.12.3 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Product Portfolio
6.12.5 Vannsh Life Sciences Recent Developments/Updates
6.13 Beacon Pharmaceuticals
6.13.1 Beacon Pharmaceuticals Company Information
6.13.2 Beacon Pharmaceuticals Description and Business Overview
6.13.3 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.13.5 Beacon Pharmaceuticals Recent Developments/Updates
6.14 Drug International
6.14.1 Drug International Company Information
6.14.2 Drug International Description and Business Overview
6.14.3 Drug International Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Drug International Gastrointestinal Stromal Tumor Drug Product Portfolio
6.14.5 Drug International Recent Developments/Updates
6.15 Deciphera Pharmaceuticals
6.15.1 Deciphera Pharmaceuticals Company Information
6.15.2 Deciphera Pharmaceuticals Description and Business Overview
6.15.3 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.15.5 Deciphera Pharmaceuticals Recent Developments/Updates
6.16 CSPC Pharmaceuticals
6.16.1 CSPC Pharmaceuticals Company Information
6.16.2 CSPC Pharmaceuticals Description and Business Overview
6.16.3 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.16.5 CSPC Pharmaceuticals Recent Developments/Updates
6.17 Hansoh Pharmaceuticals
6.17.1 Hansoh Pharmaceuticals Company Information
6.17.2 Hansoh Pharmaceuticals Description and Business Overview
6.17.3 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.17.5 Hansoh Pharmaceuticals Recent Developments/Updates
6.18 Kelun Pharmaceuticals
6.18.1 Kelun Pharmaceuticals Company Information
6.18.2 Kelun Pharmaceuticals Description and Business Overview
6.18.3 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.18.5 Kelun Pharmaceuticals Recent Developments/Updates
6.19 Zai Lab
6.19.1 Zai Lab Company Information
6.19.2 Zai Lab Description and Business Overview
6.19.3 Zai Lab Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.19.4 Zai Lab Gastrointestinal Stromal Tumor Drug Product Portfolio
6.19.5 Zai Lab Recent Developments/Updates
6.20 CStone Pharmaceuticals
6.20.1 CStone Pharmaceuticals Company Information
6.20.2 CStone Pharmaceuticals Description and Business Overview
6.20.3 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.20.4 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.20.5 CStone Pharmaceuticals Recent Developments/Updates
6.21 China Biopharmaceuticals
6.21.1 China Biopharmaceuticals Company Information
6.21.2 China Biopharmaceuticals Description and Business Overview
6.21.3 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue, and Gross Margin (2021–2026)
6.21.4 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.21.5 China Biopharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Gastrointestinal Stromal Tumor Drug Industry Chain Analysis
7.2 Gastrointestinal Stromal Tumor Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Gastrointestinal Stromal Tumor Drug Production Mode & Process Analysis
7.4 Gastrointestinal Stromal Tumor Drug Sales and Marketing
7.4.1 Gastrointestinal Stromal Tumor Drug Sales Channels
7.4.2 Gastrointestinal Stromal Tumor Drug Distributors
7.5 Gastrointestinal Stromal Tumor Drug Customer Analysis
8 Gastrointestinal Stromal Tumor Drug Market Dynamics
8.1 Gastrointestinal Stromal Tumor Drug Industry Trends
8.2 Gastrointestinal Stromal Tumor Drug Market Drivers
8.3 Gastrointestinal Stromal Tumor Drug Market Challenges
8.4 Gastrointestinal Stromal Tumor Drug Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Gastrointestinal Stromal Tumor Drug Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Gastrointestinal Stromal Tumor Drug Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Gastrointestinal Stromal Tumor Drug Market Competitive Situation by Manufacturers in 2025
Table 4. Global Gastrointestinal Stromal Tumor Drug Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Gastrointestinal Stromal Tumor Drug Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Gastrointestinal Stromal Tumor Drug Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Gastrointestinal Stromal Tumor Drug Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Gastrointestinal Stromal Tumor Drug, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Gastrointestinal Stromal Tumor Drug, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Gastrointestinal Stromal Tumor Drug, Product Types and Applications
Table 12. Global Key Manufacturers of Gastrointestinal Stromal Tumor Drug, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Gastrointestinal Stromal Tumor Drug Companies by Tier (Tier 1, Tier 2, Tier 3), based on Gastrointestinal Stromal Tumor Drug Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Gastrointestinal Stromal Tumor Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Gastrointestinal Stromal Tumor Drug Sales by Region (K Units), 2021–2026
Table 18. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Region (2021–2026)
Table 19. Global Gastrointestinal Stromal Tumor Drug Sales by Region (K Units), 2027–2032
Table 20. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Region (2027–2032)
Table 21. Global Gastrointestinal Stromal Tumor Drug Revenue by Region (US$ Million), 2021–2026
Table 22. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Region (2021–2026)
Table 23. Global Gastrointestinal Stromal Tumor Drug Revenue by Region (US$ Million), 2027–2032
Table 24. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Region (2027–2032)
Table 25. North America Gastrointestinal Stromal Tumor Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Gastrointestinal Stromal Tumor Drug Sales by Country (K Units), 2021–2026
Table 27. North America Gastrointestinal Stromal Tumor Drug Sales by Country (K Units), 2027–2032
Table 28. North America Gastrointestinal Stromal Tumor Drug Revenue by Country (US$ Million), 2021–2026
Table 29. North America Gastrointestinal Stromal Tumor Drug Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Gastrointestinal Stromal Tumor Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Gastrointestinal Stromal Tumor Drug Sales by Country (K Units), 2021–2026
Table 32. Europe Gastrointestinal Stromal Tumor Drug Sales by Country (K Units), 2027–2032
Table 33. Europe Gastrointestinal Stromal Tumor Drug Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Gastrointestinal Stromal Tumor Drug Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Gastrointestinal Stromal Tumor Drug Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Gastrointestinal Stromal Tumor Drug Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Gastrointestinal Stromal Tumor Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Gastrointestinal Stromal Tumor Drug Sales by Country (K Units), 2021–2026
Table 42. Latin America Gastrointestinal Stromal Tumor Drug Sales by Country (K Units), 2027–2032
Table 43. Latin America Gastrointestinal Stromal Tumor Drug Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Gastrointestinal Stromal Tumor Drug Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue by Country (US$ Million), 2027–2032
Table 50. Global Gastrointestinal Stromal Tumor Drug Sales (K Units) by Type (2021–2026)
Table 51. Global Gastrointestinal Stromal Tumor Drug Sales (K Units) by Type (2027–2032)
Table 52. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2021–2026)
Table 53. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2027–2032)
Table 54. Global Gastrointestinal Stromal Tumor Drug Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Gastrointestinal Stromal Tumor Drug Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2021–2026)
Table 57. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2027–2032)
Table 58. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Type (2021–2026)
Table 59. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Type (2027–2032)
Table 60. Global Gastrointestinal Stromal Tumor Drug Sales (K Units) by Application (2021–2026)
Table 61. Global Gastrointestinal Stromal Tumor Drug Sales (K Units) by Application (2027–2032)
Table 62. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2021–2026)
Table 63. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2027–2032)
Table 64. Global Gastrointestinal Stromal Tumor Drug Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Gastrointestinal Stromal Tumor Drug Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2021–2026)
Table 67. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2027–2032)
Table 68. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Application (2021–2026)
Table 69. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Application (2027–2032)
Table 70. Novartis Company Information
Table 71. Novartis Description and Business Overview
Table 72. Novartis Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Novartis Gastrointestinal Stromal Tumor Drug Product
Table 74. Novartis Recent Developments/Updates
Table 75. Bayer Pharmaceuticals Company Information
Table 76. Bayer Pharmaceuticals Description and Business Overview
Table 77. Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
Table 79. Bayer Pharmaceuticals Recent Developments/Updates
Table 80. Glenmark Pharmaceuticals Ltd. Company Information
Table 81. Glenmark Pharmaceuticals Ltd. Description and Business Overview
Table 82. Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Product
Table 84. Glenmark Pharmaceuticals Ltd. Recent Developments/Updates
Table 85. Sun Pharmaceuticals Company Information
Table 86. Sun Pharmaceuticals Description and Business Overview
Table 87. Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
Table 89. Sun Pharmaceuticals Recent Developments/Updates
Table 90. Actavis Generics Company Information
Table 91. Actavis Generics Description and Business Overview
Table 92. Actavis Generics Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Actavis Generics Gastrointestinal Stromal Tumor Drug Product
Table 94. Actavis Generics Recent Developments/Updates
Table 95. Dr. Reddy's Laboratories Company Information
Table 96. Dr. Reddy's Laboratories Description and Business Overview
Table 97. Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Product
Table 99. Dr. Reddy's Laboratories Recent Developments/Updates
Table 100. Teva Pharmaceutical Industries Ltd. Company Information
Table 101. Teva Pharmaceutical Industries Ltd. Description and Business Overview
Table 102. Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Product
Table 104. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 105. Apotex Inc. Company Information
Table 106. Apotex Inc. Description and Business Overview
Table 107. Apotex Inc. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Apotex Inc. Gastrointestinal Stromal Tumor Drug Product
Table 109. Apotex Inc. Recent Developments/Updates
Table 110. Mylan Pharms Inc. Company Information
Table 111. Mylan Pharms Inc. Description and Business Overview
Table 112. Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Product
Table 114. Mylan Pharms Inc. Recent Developments/Updates
Table 115. Bulat Pharmaceutical Company Information
Table 116. Bulat Pharmaceutical Description and Business Overview
Table 117. Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Product
Table 119. Bulat Pharmaceutical Recent Developments/Updates
Table 120. MSN Laboratories Company Information
Table 121. MSN Laboratories Description and Business Overview
Table 122. MSN Laboratories Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. MSN Laboratories Gastrointestinal Stromal Tumor Drug Product
Table 124. MSN Laboratories Recent Developments/Updates
Table 125. Vannsh Life Sciences Company Information
Table 126. Vannsh Life Sciences Description and Business Overview
Table 127. Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Product
Table 129. Vannsh Life Sciences Recent Developments/Updates
Table 130. Beacon Pharmaceuticals Company Information
Table 131. Beacon Pharmaceuticals Description and Business Overview
Table 132. Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
Table 134. Beacon Pharmaceuticals Recent Developments/Updates
Table 135. Drug International Company Information
Table 136. Drug International Description and Business Overview
Table 137. Drug International Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. Drug International Gastrointestinal Stromal Tumor Drug Product
Table 139. Drug International Recent Developments/Updates
Table 140. Deciphera Pharmaceuticals Company Information
Table 141. Deciphera Pharmaceuticals Description and Business Overview
Table 142. Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
Table 144. Deciphera Pharmaceuticals Recent Developments/Updates
Table 145. CSPC Pharmaceuticals Company Information
Table 146. CSPC Pharmaceuticals Description and Business Overview
Table 147. CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 148. CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
Table 149. CSPC Pharmaceuticals Recent Developments/Updates
Table 150. Hansoh Pharmaceuticals Company Information
Table 151. Hansoh Pharmaceuticals Description and Business Overview
Table 152. Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 153. Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
Table 154. Hansoh Pharmaceuticals Recent Developments/Updates
Table 155. Kelun Pharmaceuticals Company Information
Table 156. Kelun Pharmaceuticals Description and Business Overview
Table 157. Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 158. Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
Table 159. Kelun Pharmaceuticals Recent Developments/Updates
Table 160. Zai Lab Company Information
Table 161. Zai Lab Description and Business Overview
Table 162. Zai Lab Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 163. Zai Lab Gastrointestinal Stromal Tumor Drug Product
Table 164. Zai Lab Recent Developments/Updates
Table 165. CStone Pharmaceuticals Company Information
Table 166. CStone Pharmaceuticals Description and Business Overview
Table 167. CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 168. CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
Table 169. CStone Pharmaceuticals Recent Developments/Updates
Table 170. China Biopharmaceuticals Company Information
Table 171. China Biopharmaceuticals Description and Business Overview
Table 172. China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 173. China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Product
Table 174. China Biopharmaceuticals Recent Developments/Updates
Table 175. Key Raw Materials Lists
Table 176. Raw Materials Key Suppliers Lists
Table 177. Gastrointestinal Stromal Tumor Drug Distributors List
Table 178. Gastrointestinal Stromal Tumor Drug Customers List
Table 179. Gastrointestinal Stromal Tumor Drug Market Trends
Table 180. Gastrointestinal Stromal Tumor Drug Market Drivers
Table 181. Gastrointestinal Stromal Tumor Drug Market Challenges
Table 182. Gastrointestinal Stromal Tumor Drug Market Restraints
Table 183. Research Programs/Design for This Report
Table 184. Key Data Information from Secondary Sources
Table 185. Key Data Information from Primary Sources
Table 186. Authors List of This Report
List of Figures
Figure 1. Product Picture of Gastrointestinal Stromal Tumor Drug
Figure 2. Global Gastrointestinal Stromal Tumor Drug Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Gastrointestinal Stromal Tumor Drug Market Share by Type: 2025 & 2032
Figure 4. Imatinib Product Picture
Figure 5. Sunitinib Product Picture
Figure 6. Regorafenib Product Picture
Figure 7. Ripretinib Product Picture
Figure 8. Others Product Picture
Figure 9. Global Gastrointestinal Stromal Tumor Drug Market Value by Application (US$ Million), 2021–2032
Figure 10. Global Gastrointestinal Stromal Tumor Drug Market Share by Application: 2025 & 2032
Figure 11. Hospital
Figure 12. Clinic
Figure 13. Others
Figure 14. Global Gastrointestinal Stromal Tumor Drug Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Gastrointestinal Stromal Tumor Drug Market Size (US$ Million), 2021–2032
Figure 16. Global Gastrointestinal Stromal Tumor Drug Sales (K Units), 2021–2032
Figure 17. Global Gastrointestinal Stromal Tumor Drug Average Price (US$/Unit), 2021–2032
Figure 18. Gastrointestinal Stromal Tumor Drug Report Years Considered
Figure 19. Gastrointestinal Stromal Tumor Drug Sales Share by Manufacturers in 2025
Figure 20. Global Gastrointestinal Stromal Tumor Drug Revenue Share by Manufacturers in 2025
Figure 21. Top 5 and Top 10 Global Gastrointestinal Stromal Tumor Drug Players: Market Share by Revenue in Gastrointestinal Stromal Tumor Drug in 2025
Figure 22. Gastrointestinal Stromal Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 23. Global Gastrointestinal Stromal Tumor Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 24. North America Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021–2032)
Figure 25. North America Gastrointestinal Stromal Tumor Drug Revenue Market Share by Country (2021–2032)
Figure 26. United States Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Canada Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. Europe Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021–2032)
Figure 29. Europe Gastrointestinal Stromal Tumor Drug Revenue Market Share by Country (2021–2032)
Figure 30. Germany Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. France Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. U.K. Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Italy Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Russia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Asia Pacific Gastrointestinal Stromal Tumor Drug Sales Market Share by Region (2021–2032)
Figure 36. Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue Market Share by Region (2021–2032)
Figure 37. China Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Japan Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. South Korea Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. India Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Australia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. China Taiwan Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Southeast Asia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Latin America Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021–2032)
Figure 45. Latin America Gastrointestinal Stromal Tumor Drug Revenue Market Share by Country (2021–2032)
Figure 46. Mexico Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Brazil Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Argentina Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Colombia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021–2032)
Figure 51. Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue Market Share by Country (2021–2032)
Figure 52. Turkey Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Saudi Arabia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. UAE Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Global Sales Market Share of Gastrointestinal Stromal Tumor Drug by Type (2021–2032)
Figure 56. Global Revenue Market Share of Gastrointestinal Stromal Tumor Drug by Type (2021–2032)
Figure 57. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Type (2021–2032)
Figure 58. Global Sales Market Share of Gastrointestinal Stromal Tumor Drug by Application (2021–2032)
Figure 59. Global Revenue Market Share of Gastrointestinal Stromal Tumor Drug by Application (2021–2032)
Figure 60. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Application (2021–2032)
Figure 61. Gastrointestinal Stromal Tumor Drug Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Table 1. Global Gastrointestinal Stromal Tumor Drug Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Gastrointestinal Stromal Tumor Drug Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Gastrointestinal Stromal Tumor Drug Market Competitive Situation by Manufacturers in 2025
Table 4. Global Gastrointestinal Stromal Tumor Drug Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Gastrointestinal Stromal Tumor Drug Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Gastrointestinal Stromal Tumor Drug Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Gastrointestinal Stromal Tumor Drug Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Gastrointestinal Stromal Tumor Drug, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Gastrointestinal Stromal Tumor Drug, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Gastrointestinal Stromal Tumor Drug, Product Types and Applications
Table 12. Global Key Manufacturers of Gastrointestinal Stromal Tumor Drug, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Gastrointestinal Stromal Tumor Drug Companies by Tier (Tier 1, Tier 2, Tier 3), based on Gastrointestinal Stromal Tumor Drug Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Gastrointestinal Stromal Tumor Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Gastrointestinal Stromal Tumor Drug Sales by Region (K Units), 2021–2026
Table 18. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Region (2021–2026)
Table 19. Global Gastrointestinal Stromal Tumor Drug Sales by Region (K Units), 2027–2032
Table 20. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Region (2027–2032)
Table 21. Global Gastrointestinal Stromal Tumor Drug Revenue by Region (US$ Million), 2021–2026
Table 22. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Region (2021–2026)
Table 23. Global Gastrointestinal Stromal Tumor Drug Revenue by Region (US$ Million), 2027–2032
Table 24. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Region (2027–2032)
Table 25. North America Gastrointestinal Stromal Tumor Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Gastrointestinal Stromal Tumor Drug Sales by Country (K Units), 2021–2026
Table 27. North America Gastrointestinal Stromal Tumor Drug Sales by Country (K Units), 2027–2032
Table 28. North America Gastrointestinal Stromal Tumor Drug Revenue by Country (US$ Million), 2021–2026
Table 29. North America Gastrointestinal Stromal Tumor Drug Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Gastrointestinal Stromal Tumor Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Gastrointestinal Stromal Tumor Drug Sales by Country (K Units), 2021–2026
Table 32. Europe Gastrointestinal Stromal Tumor Drug Sales by Country (K Units), 2027–2032
Table 33. Europe Gastrointestinal Stromal Tumor Drug Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Gastrointestinal Stromal Tumor Drug Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Gastrointestinal Stromal Tumor Drug Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Gastrointestinal Stromal Tumor Drug Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Gastrointestinal Stromal Tumor Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Gastrointestinal Stromal Tumor Drug Sales by Country (K Units), 2021–2026
Table 42. Latin America Gastrointestinal Stromal Tumor Drug Sales by Country (K Units), 2027–2032
Table 43. Latin America Gastrointestinal Stromal Tumor Drug Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Gastrointestinal Stromal Tumor Drug Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue by Country (US$ Million), 2027–2032
Table 50. Global Gastrointestinal Stromal Tumor Drug Sales (K Units) by Type (2021–2026)
Table 51. Global Gastrointestinal Stromal Tumor Drug Sales (K Units) by Type (2027–2032)
Table 52. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2021–2026)
Table 53. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2027–2032)
Table 54. Global Gastrointestinal Stromal Tumor Drug Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Gastrointestinal Stromal Tumor Drug Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2021–2026)
Table 57. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2027–2032)
Table 58. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Type (2021–2026)
Table 59. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Type (2027–2032)
Table 60. Global Gastrointestinal Stromal Tumor Drug Sales (K Units) by Application (2021–2026)
Table 61. Global Gastrointestinal Stromal Tumor Drug Sales (K Units) by Application (2027–2032)
Table 62. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2021–2026)
Table 63. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2027–2032)
Table 64. Global Gastrointestinal Stromal Tumor Drug Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Gastrointestinal Stromal Tumor Drug Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2021–2026)
Table 67. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2027–2032)
Table 68. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Application (2021–2026)
Table 69. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Application (2027–2032)
Table 70. Novartis Company Information
Table 71. Novartis Description and Business Overview
Table 72. Novartis Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Novartis Gastrointestinal Stromal Tumor Drug Product
Table 74. Novartis Recent Developments/Updates
Table 75. Bayer Pharmaceuticals Company Information
Table 76. Bayer Pharmaceuticals Description and Business Overview
Table 77. Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
Table 79. Bayer Pharmaceuticals Recent Developments/Updates
Table 80. Glenmark Pharmaceuticals Ltd. Company Information
Table 81. Glenmark Pharmaceuticals Ltd. Description and Business Overview
Table 82. Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Product
Table 84. Glenmark Pharmaceuticals Ltd. Recent Developments/Updates
Table 85. Sun Pharmaceuticals Company Information
Table 86. Sun Pharmaceuticals Description and Business Overview
Table 87. Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
Table 89. Sun Pharmaceuticals Recent Developments/Updates
Table 90. Actavis Generics Company Information
Table 91. Actavis Generics Description and Business Overview
Table 92. Actavis Generics Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Actavis Generics Gastrointestinal Stromal Tumor Drug Product
Table 94. Actavis Generics Recent Developments/Updates
Table 95. Dr. Reddy's Laboratories Company Information
Table 96. Dr. Reddy's Laboratories Description and Business Overview
Table 97. Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Product
Table 99. Dr. Reddy's Laboratories Recent Developments/Updates
Table 100. Teva Pharmaceutical Industries Ltd. Company Information
Table 101. Teva Pharmaceutical Industries Ltd. Description and Business Overview
Table 102. Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Product
Table 104. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 105. Apotex Inc. Company Information
Table 106. Apotex Inc. Description and Business Overview
Table 107. Apotex Inc. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Apotex Inc. Gastrointestinal Stromal Tumor Drug Product
Table 109. Apotex Inc. Recent Developments/Updates
Table 110. Mylan Pharms Inc. Company Information
Table 111. Mylan Pharms Inc. Description and Business Overview
Table 112. Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Product
Table 114. Mylan Pharms Inc. Recent Developments/Updates
Table 115. Bulat Pharmaceutical Company Information
Table 116. Bulat Pharmaceutical Description and Business Overview
Table 117. Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Product
Table 119. Bulat Pharmaceutical Recent Developments/Updates
Table 120. MSN Laboratories Company Information
Table 121. MSN Laboratories Description and Business Overview
Table 122. MSN Laboratories Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. MSN Laboratories Gastrointestinal Stromal Tumor Drug Product
Table 124. MSN Laboratories Recent Developments/Updates
Table 125. Vannsh Life Sciences Company Information
Table 126. Vannsh Life Sciences Description and Business Overview
Table 127. Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Product
Table 129. Vannsh Life Sciences Recent Developments/Updates
Table 130. Beacon Pharmaceuticals Company Information
Table 131. Beacon Pharmaceuticals Description and Business Overview
Table 132. Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
Table 134. Beacon Pharmaceuticals Recent Developments/Updates
Table 135. Drug International Company Information
Table 136. Drug International Description and Business Overview
Table 137. Drug International Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. Drug International Gastrointestinal Stromal Tumor Drug Product
Table 139. Drug International Recent Developments/Updates
Table 140. Deciphera Pharmaceuticals Company Information
Table 141. Deciphera Pharmaceuticals Description and Business Overview
Table 142. Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
Table 144. Deciphera Pharmaceuticals Recent Developments/Updates
Table 145. CSPC Pharmaceuticals Company Information
Table 146. CSPC Pharmaceuticals Description and Business Overview
Table 147. CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 148. CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
Table 149. CSPC Pharmaceuticals Recent Developments/Updates
Table 150. Hansoh Pharmaceuticals Company Information
Table 151. Hansoh Pharmaceuticals Description and Business Overview
Table 152. Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 153. Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
Table 154. Hansoh Pharmaceuticals Recent Developments/Updates
Table 155. Kelun Pharmaceuticals Company Information
Table 156. Kelun Pharmaceuticals Description and Business Overview
Table 157. Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 158. Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
Table 159. Kelun Pharmaceuticals Recent Developments/Updates
Table 160. Zai Lab Company Information
Table 161. Zai Lab Description and Business Overview
Table 162. Zai Lab Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 163. Zai Lab Gastrointestinal Stromal Tumor Drug Product
Table 164. Zai Lab Recent Developments/Updates
Table 165. CStone Pharmaceuticals Company Information
Table 166. CStone Pharmaceuticals Description and Business Overview
Table 167. CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 168. CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
Table 169. CStone Pharmaceuticals Recent Developments/Updates
Table 170. China Biopharmaceuticals Company Information
Table 171. China Biopharmaceuticals Description and Business Overview
Table 172. China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 173. China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Product
Table 174. China Biopharmaceuticals Recent Developments/Updates
Table 175. Key Raw Materials Lists
Table 176. Raw Materials Key Suppliers Lists
Table 177. Gastrointestinal Stromal Tumor Drug Distributors List
Table 178. Gastrointestinal Stromal Tumor Drug Customers List
Table 179. Gastrointestinal Stromal Tumor Drug Market Trends
Table 180. Gastrointestinal Stromal Tumor Drug Market Drivers
Table 181. Gastrointestinal Stromal Tumor Drug Market Challenges
Table 182. Gastrointestinal Stromal Tumor Drug Market Restraints
Table 183. Research Programs/Design for This Report
Table 184. Key Data Information from Secondary Sources
Table 185. Key Data Information from Primary Sources
Table 186. Authors List of This Report
List of Figures
Figure 1. Product Picture of Gastrointestinal Stromal Tumor Drug
Figure 2. Global Gastrointestinal Stromal Tumor Drug Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Gastrointestinal Stromal Tumor Drug Market Share by Type: 2025 & 2032
Figure 4. Imatinib Product Picture
Figure 5. Sunitinib Product Picture
Figure 6. Regorafenib Product Picture
Figure 7. Ripretinib Product Picture
Figure 8. Others Product Picture
Figure 9. Global Gastrointestinal Stromal Tumor Drug Market Value by Application (US$ Million), 2021–2032
Figure 10. Global Gastrointestinal Stromal Tumor Drug Market Share by Application: 2025 & 2032
Figure 11. Hospital
Figure 12. Clinic
Figure 13. Others
Figure 14. Global Gastrointestinal Stromal Tumor Drug Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Gastrointestinal Stromal Tumor Drug Market Size (US$ Million), 2021–2032
Figure 16. Global Gastrointestinal Stromal Tumor Drug Sales (K Units), 2021–2032
Figure 17. Global Gastrointestinal Stromal Tumor Drug Average Price (US$/Unit), 2021–2032
Figure 18. Gastrointestinal Stromal Tumor Drug Report Years Considered
Figure 19. Gastrointestinal Stromal Tumor Drug Sales Share by Manufacturers in 2025
Figure 20. Global Gastrointestinal Stromal Tumor Drug Revenue Share by Manufacturers in 2025
Figure 21. Top 5 and Top 10 Global Gastrointestinal Stromal Tumor Drug Players: Market Share by Revenue in Gastrointestinal Stromal Tumor Drug in 2025
Figure 22. Gastrointestinal Stromal Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 23. Global Gastrointestinal Stromal Tumor Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 24. North America Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021–2032)
Figure 25. North America Gastrointestinal Stromal Tumor Drug Revenue Market Share by Country (2021–2032)
Figure 26. United States Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Canada Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. Europe Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021–2032)
Figure 29. Europe Gastrointestinal Stromal Tumor Drug Revenue Market Share by Country (2021–2032)
Figure 30. Germany Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. France Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. U.K. Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Italy Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Russia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Asia Pacific Gastrointestinal Stromal Tumor Drug Sales Market Share by Region (2021–2032)
Figure 36. Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue Market Share by Region (2021–2032)
Figure 37. China Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Japan Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. South Korea Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. India Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Australia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. China Taiwan Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Southeast Asia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Latin America Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021–2032)
Figure 45. Latin America Gastrointestinal Stromal Tumor Drug Revenue Market Share by Country (2021–2032)
Figure 46. Mexico Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Brazil Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Argentina Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Colombia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021–2032)
Figure 51. Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue Market Share by Country (2021–2032)
Figure 52. Turkey Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Saudi Arabia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. UAE Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Global Sales Market Share of Gastrointestinal Stromal Tumor Drug by Type (2021–2032)
Figure 56. Global Revenue Market Share of Gastrointestinal Stromal Tumor Drug by Type (2021–2032)
Figure 57. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Type (2021–2032)
Figure 58. Global Sales Market Share of Gastrointestinal Stromal Tumor Drug by Application (2021–2032)
Figure 59. Global Revenue Market Share of Gastrointestinal Stromal Tumor Drug by Application (2021–2032)
Figure 60. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Application (2021–2032)
Figure 61. Gastrointestinal Stromal Tumor Drug Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232